Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Bristol-Myers Squibb Co.
DescriptionOral lysophosphatidic acid receptor 1 (LPA1) antagonist
Molecular Target Lysophosphatidic acid receptor 1 (LPAR1) (EDG2) (LPA1)
Mechanism of ActionLysophosphatidic acid receptor antagonist
Therapeutic Modality 
Latest Stage of DevelopmentPreclinical
Standard IndicationScleroderma
Indication DetailsTreat fibrosis; Treat scleroderma
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today